The efficacy and safety of Helicobacter pylori eradication therapy using vonoprazan

The efficacy and safety of Helicobacter pylori eradication therapy using vonoprazan - The efficacy and safety of H. pylori eradication therapy using vonoprazan

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021824

Enrollment

800

Registered

2016-04-07

Start date

2016-03-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection

Interventions

1st line triple therapy) Vonoprazan 20mg bid Amoxicillin 750mg bid Clarithromycin 200mg bid daily for 7 days 2nd line triple therapy) Vonoprazan 20mg bid Amoxicillin 750mg bid Metronidazole

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Cases with Helicobacter pylori infection. Cases with written and oral informed consent.

Exclusion criteria

Exclusion criteria: Past history of allergy for these medications, Vonoprazan, Amoxicillin, Clarithromycin, and Metronidazole used in this therapy.

Design outcomes

Primary

Measure	Time frame
The rate of Helicobacter pylori eradication using 1st line triple therapy and 2nd line triple therapy	—

Secondary

Measure	Time frame
The rate of side effects	—

Countries

Japan

Contacts

Public ContactEsaki Masaya

Medical corporation Yamashita Hospital Gastroenterology

b.b.player6089@gmail.com0586-45-4511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026